Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

CGENAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ722.18+ 1.40%S&P 500 · SPY769.66+ 0.56%Dow Jones · DIA523.28+ 0.06%Russell 2000 · IWM280.18+ 1.15%

Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI, today announced that the Company will release its third quarter 2026 financial results on Monday, November 9, 2026, before the U.S. financial markets open. That same day, management will host a conference call to review the results and provide a corporate update at 8:30 AM ET.
Yahoo07:00YesterdayCGEN−0.8%

03:00Oct 121 Story

HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.
Benzinga03:30CGEN−0.8%

07:00Oct 61 Story

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference, being held virtually on October 8-9, 2026.
Yahoo07:00CGEN−0.8%

10:00-18:00Oct 52 Stories

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event. President and Chief Executive Officer Er
Yahoo17:02CGEN−0.8%
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements October 5, 2026 8:00 AM EDTCompany...
SeekingAlpha10:30CGEN−0.8%

07:00Sep 221 Story

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced it will host a virtual key opinion leader (KOL) event on Monday, October 5, 2026 at 8:00 AM ET featuring Oladapo Yeku, M.D., Ph.D., FACP (Harvard Medical School, Massachusetts General Hospital), who will join company management to discuss COM701 and the evolving treatment landscape in ovarian cancer. To register, click here.
Yahoo07:00CGEN−0.8%

07:00Sep 81 Story

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, being held from September 14-16 in New York City.
Yahoo07:00CGEN−0.8%

19:00Aug 61 Story

Compugen: Better Runway Ahead Of MAIA
SeekingAlpha19:59CGEN−0.8%

03:00-07:00Aug 32 Stories

Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Compugen Ltd. (CGEN) Q2 2026 Earnings Call August 3, 2026 8:30 AM EDTCompany ParticipantsLindsey TrickettEran Ophir - CEO, President & DirectorDavid...
SeekingAlpha06:59CGEN−0.8%
Compugen Q2 EPS $(0.07), Inline, Sales $2.602M Beat $1.606M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 12.5 percent increase over losses of $(0.08) per share from the same period last year. The
Benzinga03:01CGEN−0.8%